Stevens J B, Vescovo M V, Harris K C, Walker S C, Hickey R
Department of Anesthesiology, Brooke Army Medical Center and University of Texas Health Science Center at San Antonio, 78234, USA.
Anesth Analg. 1997 Jun;84(6):1222-6. doi: 10.1097/00000539-199706000-00009.
Administration of alfentanil followed by propofol intravenously (IV) without neuromuscular blockade for induction of anesthesia provides adequate conditions for tracheal intubation. Other hypnotic drugs have not been thoroughly investigated in this regard. Accordingly, 140 ASA physical status I and II premedicated outpatients were randomly assigned to one of seven groups (n = 20/group). Patients in Groups I-VI received alfentanil 40 microg/kg followed by etomidate 0.3 mg/kg, propofol 2 mg/kg, or thiopental 4 mg/kg. One half of these patients (Groups II, IV, VI) also received lidocaine 1 mg/kg IV prior to the administration of the above drugs. Patients in group VII received d-tubocurarine 3 mg followed by thiopental 4 mg/kg and succinylcholine 1 mg/kg. Ninety seconds after induction, laryngoscopy and endotracheal intubation were attempted and graded. Patients in Group V (alfentanil/thiopental) were significantly (P < 0.05) more likely to have a clinically unacceptable response to intubation (55%) (e.g., vigorous coughing, purposeful movement, or requirement for succinylcholine to complete intubation) compared with patients who received propofol (35%) or etomidate (20%). Alfentanil/etomidate yielded intubation conditions comparable to those achieved with alfentanil/propofol and d-tubocurarine/thiopental/succinylcholine. Lidocaine appeared to improve intubating conditions, although this improvement did not reach statistical significance. The results suggest that healthy, premedicated patients with favorable airway anatomy who have received alfentanil 40 microg/kg can be reliably tracheally intubated 90 s after administration of propofol 2 mg/kg or etomidate 0.3 mg/kg.
在无神经肌肉阻滞的情况下,静脉注射阿芬太尼后再注射丙泊酚用于麻醉诱导,可为气管插管提供充分条件。在这方面,其他催眠药物尚未得到充分研究。因此,将140例接受术前用药的美国麻醉医师协会(ASA)身体状况I级和II级门诊患者随机分为七组(每组n = 20)。I - VI组患者先接受40μg/kg阿芬太尼,随后分别接受依托咪酯0.3mg/kg、丙泊酚2mg/kg或硫喷妥钠4mg/kg。这些患者中有一半(II、IV、VI组)在给予上述药物前还静脉注射了1mg/kg利多卡因。VII组患者先接受3mg右旋筒箭毒碱,随后接受4mg/kg硫喷妥钠和1mg/kg琥珀酰胆碱。诱导90秒后,尝试进行喉镜检查和气管插管并分级。与接受丙泊酚(35%)或依托咪酯(20%)的患者相比,V组(阿芬太尼/硫喷妥钠)患者对插管出现临床不可接受反应(如剧烈咳嗽、有目的的运动或需要琥珀酰胆碱来完成插管) 的可能性显著更高(P < 0.05)(55%)。阿芬太尼/依托咪酯产生的插管条件与阿芬太尼/丙泊酚以及右旋筒箭毒碱/硫喷妥钠/琥珀酰胆碱所达到的条件相当。利多卡因似乎改善了插管条件,尽管这种改善未达到统计学意义。结果表明,接受40μg/kg阿芬太尼的健康、接受术前用药且气道解剖结构良好的患者,在给予2mg/kg丙泊酚或0.3mg/kg依托咪酯90秒后能够可靠地进行气管插管。